Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.
about
Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatmentA C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding riskPharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumonEffect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysisThe allele frequency of CYP2C9 and VKORC1 in the Southern Khorasan population.Analysis of gene-gene interactions using gene-trait similarity regression.Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.Positive selection in the chromosome 16 VKORC1 genomic region has contributed to the variability of anticoagulant response in humansGenome-wide haplotype analysis of cis expression quantitative trait loci in monocytesWarfarin dosage response related pharmacogenetics in Chinese population.Lack of association of variants previously associated with anti-TNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek populationAnalysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe.Association of warfarin dose with genes involved in its action and metabolism.Evaluation of genetic factors for warfarin dose predictionPrediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters.A case study of acenocoumarol sensitivity and genotype-phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9.Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) - study protocol for a pragmatic randomized controlled trial.Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione.Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirementClinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after rheumatic valve replacement: a randomized and controlled trial.Effects of VKORC1 Genetic Polymorphisms on Warfarin Maintenance Dose Requirement in a Chinese Han Population.Personalized approach of medication by indirect anticoagulants tailored to the patient-Russian context: what are the prospects?Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trialContribution of CYP2C9 to variability in vitamin K antagonist metabolism.Can pharmacogenetics help rescue drugs withdrawn from the market?Pharmacogenetics of warfarin: current status and future challenges.Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia.Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patientsGenetic variation and haplotype structure of the gene Vitamin K epoxide reductase complex, subunit 1 in the Tamilian population.Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.Pharmacogenetic typing for oral anti-coagulant response among factor V Leiden mutation carriers.VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-AmericansEvolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia.Relationship between VKORC1 single nucleotide polymorphism 1173C>T, bone mineral density & carotid intima-media thicknessThe effects of ferulic acid on the pharmacokinetics of warfarin in rats after biliary drainage.Genetic variations and their influence on risk and treatment of venous thrombosis.Pharmacogenetic testing: Current Evidence of Clinical Utility.
P2860
Q24310184-021F7620-791F-4B87-A9FF-28FA0D386749Q24817078-8CD43D23-CF31-4111-9DBB-27A5B95B91C4Q27006860-231F4AA8-5A7E-46EE-B471-A2F813068818Q28276605-C234FF95-11EF-4429-BD6E-DC571FC4E4FFQ33782314-06156358-FD25-4F99-B823-F597630DF8E7Q33970683-D72E8078-BEF8-4F88-8D42-6D39F8095082Q34131354-5FE9C2EE-EF93-46E8-B674-8C3A231572ADQ34179616-7496632B-F746-49BE-8E04-AB40ACA8D074Q34362277-AB60297D-DDE6-4BD1-A802-217F103571BEQ34418092-79B83B09-83EA-4A97-B1A7-07988DF051D7Q34534993-23592C17-48B4-41D0-AE2E-395105C5C2E3Q34574923-2C667155-8350-4F51-8FC4-635D56E9DDAEQ34977531-9EC43AF3-F115-43BB-8A0E-70BF9E71F5DDQ34989977-0F350675-4ED6-4954-BED5-615BFD44413FQ35370240-806ABDFA-C66A-40D5-BEAC-B3EBB8D44A7DQ35633802-2D27DD5D-7B8E-43CB-87F6-46B193F33655Q35758421-95D19350-DB93-4CBA-8580-512E10AF701FQ35795269-CC70D5C2-1574-4FB8-8FB4-A5FDBE0DD7FBQ35827860-26270C07-BA05-4C7D-AAEA-B47E588F73EBQ35998552-132EF137-A8B6-4AD4-B747-8C51AE098B9AQ36017389-09AB9958-D44F-4A08-9387-C82E69FFF565Q36062295-D87C5657-C93F-4426-94AA-38870272CD00Q36190185-6038FE67-3FF2-48B7-AE88-42EFA1B35FBEQ36314728-7C07BF97-312F-4D86-8D8A-1182518A18D3Q36380430-F5036AAC-9FDF-4172-80D6-F682210C2C57Q36527206-D53395BD-30B7-4D06-8ABA-1D463EBD990AQ36545011-9805E4FE-98CA-4F7B-9F0C-424ECA2BD18CQ36596713-C0017D6D-5558-4E51-B26C-FA391B6BBB6BQ36597343-EBD0A984-8A07-4D0B-B8C6-3FC5780658C2Q36689156-86B650AD-6DDC-4E34-BE99-9C4DDF4F3A5DQ36741112-091E069D-0883-4E0D-B32D-D080364A0EFEQ36813817-27363181-12B3-4ECB-8A7F-E6FCB50A7088Q36835168-41AE6E93-CEE9-44E8-ACE2-8BE6659A5E42Q36851081-A8A8765A-E3B4-4A12-A7AC-CA03CEB998C1Q36982736-7146C46E-40F1-4B34-B297-052C7034C5B7Q36985872-DD9EF56B-EB43-4447-902D-24A4EBB290E0Q37047223-83A68702-ABA6-4203-BEE8-852B4CE2DACDQ37082800-9585ACCC-88B5-4F1C-9C59-4BFFF4F73A04Q37126654-8CDD7253-9C92-452A-8225-94AA803B17F2Q37151528-D9F823AF-2112-4649-A6E4-59386BA89197
P2860
Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Cytochrome P450 2C9 (CYP2C9) a ...... of acenocoumarol sensitivity.
@en
type
label
Cytochrome P450 2C9 (CYP2C9) a ...... of acenocoumarol sensitivity.
@en
prefLabel
Cytochrome P450 2C9 (CYP2C9) a ...... of acenocoumarol sensitivity.
@en
P2093
P50
P1433
P1476
Cytochrome P450 2C9 (CYP2C9) a ...... s of acenocoumarol sensitivity
@en
P2093
Annie Robert
Céline Verstuyft
Laurent Becquemont
Laurent Bodin
Liliane Dubert
Patrice Jaillon
P304
P356
10.1182/BLOOD-2005-01-0341
P407
P50
P577
2005-03-24T00:00:00Z